
Saad Z. Usmani, MD, MBA, FACP, discusses noteworthy data presented at ASH 2024, including the IFM2017-03 trial, and shares his excitement for ongoing research efforts in multiple myeloma, emphasizing key areas where further investigation is needed to improve patient outcomes and refine treatment strategies.